Phase 3 Readout~month

Phase 3 Topline: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Indication
Cancer; Prostate Cancer; Hepatocellular Carcinoma (HCC)

Other upcoming events for EXEL

Patent ExpiryPatent/Exclusivity Expiry: SUPREP BOWEL PREP KIT
Patent ExpiryPatent/Exclusivity Expiry: XYWAV
Patent ExpiryPatent/Exclusivity Expiry: PREPOPIK
Phase 3 ReadoutPhase 3 Topline: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants
Patent ExpiryPatent/Exclusivity Expiry: OFEV

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study — EXEL Phase 3 Readout | BioSniper